22:36 , Dec 7, 2018 |  BioCentury  |  Finance

Taking Tesaro

While the $5.1 billion takeout price for Tesaro Inc. (NASDAQ:TSRO) is a far cry from its $9.8 billion peak valuation, investors who spoke with BioCentury see the final price tag as a fair value. GlaxoSmithKline...
22:07 , Dec 3, 2018 |  BC Extra  |  Company News

NIH may give ElevateBio exclusive CAR T license

NIH's National Cancer Institute is considering granting ElevateBio LLC (Cambridge, Mass.) an exclusive license to develop an undisclosed CAR T therapy targeting FMS-like tyrosine kinase 3 (FLT3; CD135). In a Federal Registry notice , NIH...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
15:59 , Nov 16, 2018 |  BC Week In Review  |  Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed on Nov. 9 to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship...
01:39 , Nov 10, 2018 |  BC Extra  |  Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship Pioneering launched Moderna...
17:27 , Nov 9, 2018 |  BC Week In Review  |  Financial News

Perceptive doubles up for second debt fund

Perceptive Advisors LLC closed on Nov. 5 its second debt fund, Perceptive Credit Opportunities Fund II, at $675 million, above its $500 million target. The figure is twice that of its first debt fund, which...
22:07 , Nov 5, 2018 |  BC Extra  |  Financial News

Perceptive doubles up for second debt fund

Perceptive Advisors LLC closed its second debt fund Perceptive Credit Opportunities Fund II at $675 million, above its $500 million target. The figure is twice that of its first debt fund, which closed at $323...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
18:04 , Oct 12, 2018 |  BC Week In Review  |  Financial News

First-day pop for Allogene after year's largest biotech IPO on NASDAQ

Less than a year after it was founded, cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $324 million late Oct. 10 in the largest IPO by a biotech on NASDAQ thus far in 2018. The...
02:40 , Oct 11, 2018 |  BC Extra  |  Financial News

First-day pop for Allogene after year's largest biotech IPO on NASDAQ

Less than a year after it was founded, cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $324 million late Wednesday in the largest IPO by a biotech on NASDAQ thus far in 2018. The company...